UBS Group
IBER.U

UBS Group’s Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant IBER.U Stock Holding History

UBS Group’s Portfolio IBER.U Stock Details IBER.U Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-600
Closed -$5.98K – 11357
2022
Q4 		$5.98K Hold
600
– – ﹤0.01% 9099
2022
Q3 		$6K Buy
600
+260
+76% +$2.57K ﹤0.01% 9135
2022
Q2 		$3K Hold
340
– – ﹤0.01% 9456
2022
Q1 		$3K Hold
340
– – ﹤0.01% 9559
2021
Q4 		$3K Buy
+340
New +$3.39K ﹤0.01% 9742
2021
Q2 		– Sell
-840
Closed -$8K – 10076
2021
Q1 		$8K Buy
+840
New +$8.4K ﹤0.01% 8115

UBS Group's IBER.U Position: Q1 2023 in Review

UBS Group sold out of Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant (IBER.U) in Q1 2023, closing a stake of 600 shares — an estimated $5.98K sold.

UBS Group first reported a position in IBER.U in Q1 2021 and held it in 6 quarters. The position peaked at $8K in Q1 2021. 0 funds tracked by Wall St. Rank hold IBER.U as of Q1 2023.

  • UBS Group reported no remaining Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant position as of Q1 2023 after selling out during the quarter.
  • UBS Group sold 600 Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant shares in Q1 2023, an estimated $5.98K.
  • UBS Group first reported a position in Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant in Q1 2021 and held it in 6 quarters.
  • UBS Group's Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant position peaked at $8K in Q1 2021.
  • 0 funds tracked by Wall St. Rank held Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant as of Q1 2023.

Based on UBS Group's 13F filing for Q1 2023, filed 12 May 2023.